Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pemetrexed and Pembrolizumab in Recurrent and/or Metastatic Salivary Gland Malignancies

NCT04895735 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04895735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04895735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pemetrexed and Pembrolizumab in Recurrent and/or Metastatic Salivary Gland Malignancies
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 23, 2021
Completion date
February 28, 2028
Enrollment
45 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, metastatic salivary gland carcinoma, recurrent salivary gland carcinoma, stage iv major salivary gland cancer ajcc v8